Moleculin Biotech, Inc. (MBRX) received a delisting determination letter from Nasdaq on September 15, 2026, for failing to meet the $1.00 minimum bid price requirement. The company's stock traded below this threshold for 30 consecutive business days. Due to a reverse stock split within the last year, the company is not eligible for the standard 180-day compliance period and intends to appeal the decision.
Key Details
- Reason for Notice: The company's common stock closing bid price was below $1.00 per share for 30 consecutive business days, from July 31, 2026, to September 11, 2026.
- Ineligibility for Compliance Period: Moleculin is not eligible for the standard 180-day grace period because it effected a 1-for-25 reverse stock split on December 1, 2025.
- Company Action: The company plans to request a hearing before the Nasdaq Hearings Panel to appeal the delisting. A timely request will stay any delisting action pending the panel's decision.